Immunicum’s second-quarter financial results have been superseded by significant product development and financing news. The agreement of the Phase Ib/II US protocol for ilixadencel with the FDA was an important milestone, but the negotiations on an agreement with a leading global pharmaceutical company for checkpoint inhibitor (CPI) access would be a significant endorsement. The recently proposed c SEK351m combined stock issues will be used to accelerate the manufacturing and potentially the development of ilixadencel, resulting in a cash runway until the end of 2021.
